COMMUNIQUÉS West-GlobeNewswire

Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
03/02/2026
WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting [...]
Cartesian Therapeutics Announces New Employment Inducement Grants
03/02/2026
FREDERICK, Md., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the [...]
Avacta Announces Two Key Clinical Updates to its Faridoxorubicin Program
03/02/2026
Cardiac dosing limit removed and path forward to dose selection identified LONDON and PHILADELPHIA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage [...]
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event
03/02/2026
“Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences" Featuring Serina Therapeutics’ CEO - Wednesday, February 4, 2026 Hear how FDA initiatives in 2026 may impact drug development [...]
The Ensign Group Adds Real Estate and Operations in Texas
03/02/2026
SAN JUAN CAPISTRANO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign ™ group of companies, which invest in and provide skilled nursing and senior living [...]
Adlai Nortye Announces $140.0 Million Private Placement Equity Financing
03/02/2026
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the [...]
Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity
03/02/2026
BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to [...]
HemostOD awarded CHF 2 million Innosuisse grant to support key development milestones
03/02/2026
HemostOD awarded CHF 2 million Innosuisse grant to support key development milestones Lausanne, Switzerland — 03 February 2026 – HemostOD, a private Swiss company pioneering the ex vivo manufacturing of donor-free, off- [...]
62,752 Orion Corporation A shares converted into B shares
03/02/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 3 FEBRUARY 2026 at 9.00 EET 62,752 Orion Corporation A shares converted into B shares In accordance with [...]
Zelluna promotes Emilie Gauthy to Chief Technology Officer
03/02/2026
Oslo, Norway, 03 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced the [...]
PreciseOnco research consortium awarded EUR 14.9 million IHI grant to drive breakthroughs in precision cancer treatment
03/02/2026
February 3, 2026 Co-funded by the EU’s Innovative Health Initiative (IHI), the Philips-coordinated research consortium will combine advanced medical imaging, robotic guidance technologies, and AI to standardize and [...]
Persica Pharmaceuticals' Positive Clinical Data for PP353 Treatment of Chronic Low Back Pain Published in The Lancet's eClinicalMedicine
03/02/2026
First publication of clinical efficacy data for PP353, in development for chronic Low Back Pain Trial demonstrated that PP353 delivers clinically meaningful and durable reduction in pain and disability in patients with [...]
Valneva et l'Instituto Butantan annoncent le début d'une stratégie pilote de vaccination au Brésil avec le vaccin à injection unique IXCHIQ® contre le chikunguny
03/02/2026
Valneva et l’Instituto Butantan annoncent l’initiation d’une campagne pilote de vaccination au Brésil avec le vaccin monodose contre le chikungunya IXCHIQ ® Lyon (France), Sao Paulo, (Brésil), le 3 février, 2026 – [...]
NMD Pharma announces topline results from its Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2
03/02/2026
Exploratory Phase 2a study showed consistent and clinically meaningful functional improvements across muscle strength, motor performance, and patient-reported outcomes in patients with Charcot-Marie-Tooth disease (CMT) [...]
Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day
03/02/2026
Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial disease Introduces napazimone ( [...]
Press Release: Sanofi announces the signing of a share buyback mandate for up to €1 billion
03/02/2026
Sanofi announces the signing of a share buyback mandate for up to €1 billion Paris, February 3, 2026. On January 29, 2026, Sanofi announced its intention to execute a share buyback program in 2026 of €1 billion. On [...]
Natures Aid Introduces NSF-Certified Creatine Gummy Using Cold-Processing Technology
03/02/2026
HONG KONG, China, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Natures Aid has introduced an NSF-certified creatine gummy designed to provide a convenient alternative to traditional creatine formats such as powders and capsules, [...]
Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®
03/02/2026
Lyon (France), Sao Paulo, (Brazil), February 3, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world’s largest biomedical research centers, today [...]
Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment
03/02/2026
Data published in Molecular Psychiatry Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company [...]

Pages